Coral Budesonide Coral Budesonide

X

Find Drugs in Development News & Deals for Budesonide

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

JP

0

Other Listed Suppliers

SERVICES
left grey arrow
right gray arrow
  • TABLET, EXTENDED RELEASE;ORAL - 9MG
  • AEROSOL, FOAM;RECTAL - 2MG/ACTUATION
  • SPRAY, METERED;NASAL - 0.032MG/SPRAY
  • SUSPENSION;INHALATION - 0.25MG/2ML
  • SUSPENSION;INHALATION - 0.5MG/2ML
  • SUSPENSION;INHALATION - 1MG/2ML
  • CAPSULE, DELAYED RELEASE;ORAL - 6MG
  • CAPSULE, DELAYED RELEASE;ORAL - 9MG
  • AEROSOL, METERED;INHALATION - 0.16MG/INH;0.0048MG/INH;0.009MG/INH
  • CAPSULE, DELAYED RELEASE;ORAL - 3MG
  • CAPSULE, DELAYED RELEASE;ORAL - 4MG
  • AEROSOL, METERED;INHALATION - 0.08MG/INH;0.0045MG/INH
  • AEROSOL, METERED;INHALATION - 0.16MG/INH;0.0045MG/INH
  • POWDER, METERED;INHALATION - 0.08MG/INH
  • POWDER, METERED;INHALATION - 0.16MG/INH

Details:

TAK-721 (budesonide oral suspension) is a novel mucoadherent topically active oral viscous formulation of budesonide, formulated specifically as an investigational treatment for eosinophilic esophagitis (EoE).


Lead Product(s): Budesonide

Therapeutic Area: Gastroenterology Product Name: TAK-721

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 20, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Nefecon is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. It is being investigated for primary IgA nephropathy.


Lead Product(s): Budesonide

Therapeutic Area: Nephrology Product Name: Nefecon

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 24, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Nefecon is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. It is being investigated for primary IgA nephropathy.


Lead Product(s): Budesonide

Therapeutic Area: Nephrology Product Name: Nefecon

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Calliditas Therapeutics AB

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 20, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Tarpeyo (budesonide) is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism, used for primary IgA nephropathy.


Lead Product(s): Budesonide

Therapeutic Area: Nephrology Product Name: Tarpeyo

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 18, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Nefecon is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. It is being investigated for primary IgA nephropathy.


Lead Product(s): Budesonide

Therapeutic Area: Nephrology Product Name: Nefecon

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 31, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol is the first generic version of AstraZeneca's Symbicort drug-device combination product and is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD).


Lead Product(s): Budesonide,Formoterol Fumarate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Breyna

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 31, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TARPEYO (budesonide) is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism, used for primary IgA nephropathy.


Lead Product(s): Budesonide

Therapeutic Area: Nephrology Product Name: Tarpeyo

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 21, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Budesonide is a prescription corticosteroid medicine used to help get active, mild to moderate ulcerative colitis that extends from the rectum to the sigmoid colon under control (induce remission).


Lead Product(s): Budesonide

Therapeutic Area: Gastroenterology Product Name: Uceris-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 28, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content